Bart Bergstein has a strong track record in working with life sciences companies. He is a co-founder of Forbion Capital Partners, a leading European venture capital firm. At Forbion, he invested in numerous healthcare companies and served as a non-executive director on the board of many portfolio companies. He also has operational experience, serving as CFO of Cellnovo Group SA, where he successfully executed an IPO on Euronext Paris. He started his career at ABN AMRO bank, where he initiated the life sciences team within ABN AMRO private equity, and in his last position headed the Private Equity Life Sciences Team as Managing Director Life Sciences. With his team at ABN AMRO, he built a portfolio of life sciences investments valued at EUR 100m, realizing multiple highly profitable exits. In addition to his role at ISA Pharmaceuticals, Bart holds various non-executive board positions in leading-edge life sciences companies.
Hendrik-Jan Laseur is the founder of Laseur – Lead the Change, an Amsterdam-based strategy advisory firm focused on supporting leaders in achieving lasting social impact of investments and business propositions. Prior to founding Laseur in 2010, he was Principal Advisor of the Executive Director at UNICEF. From 1992 to 2007, Hendrik-Jan Laseur worked at ABN Amro Bank in a variety of leadership and advisory positions, including roles as personal secretary to the Chairman of the bank, and as a member of the Executive Committee of ABN AMRO Switzerland. He studied economics in Groningen and Rotterdam and holds an MBA from INSEAD.
Karl Rothweiler is a co-founder of Aglaia BioMedical Ventures. Before starting Agalaia in 2003, he was involved in the founding, restructuring and funding of multiple technology-driven companies. In 1995, he founded Entity Holding B.V., a venture company focusing on early-stage companies. Karl’s management experience derives from his time at Cap Gemini, where he held the position of Director of the Finance Division with a staff of 650. Karl received his MBA from the University of Georgia, following his studies at The Netherlands School of Business, Nijenrode.
Pieter van der Meijden
Pieter van der Meijden (M.Sc.) is a member of the management team of “De Hoge Dennen” Holding B.V., a family-owned investment company. At De Hoge Dennen, he is responsible for developing strategy and implementation. He also is responsible for fund investments and the coordination of operational activities. Prior to joining De Hoge Dennen, he worked as managing partner at the investment company Berk Partners (2003-2007), as Managing Director Dutch Brand at Halder Invest (later called GIMV Nederland), and as Deputy Director at NIBC. Mr. Van der Meijden studied Business Economics at Erasmus University in Rotterdam.
Jan van de Winkel, Ph.D., is President and Chief Executive Officer of Genmab A/S, which he co-founded in Feb 1999. Genmab is a leading international biotechnology company focused on developing innovative antibody products for the potential treatment of cancer. Prior to joining Genmab, he served as Vice President and Scientific Director of Medarex Europe. Dr. van de Winkel is widely recognized as one of the leading scientists in the study of antibodies and their interaction with the immune system. He has (co-) authored more than 300 scientific publications and has been responsible for over 40 patents and patent applications. He holds a Professorship in Immunology at Utrecht University and M.S. and Ph.D. degrees from the University of Nijmegen.